B
Bristol-Myers Squibb Company (BMY)
NYQ – Real vaqt narxi. Valyuta: USD
57.52
+2.13 (3.85%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
57.40
-0.12 (-0.21%)
Bozordan keyin: Jun 26, 2026, 8:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
57.52
+2.13 (3.85%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
57.40
-0.12 (-0.21%)
Bozordan keyin: Jun 26, 2026, 8:00 PM EDT
Bristol-Myers Squibb kompaniyasi dunyo bo'ylab biofarmatsevtik mahsulotlarni kashf etadi, ishlab chiqadi, litsenziyalaydi, ishlab chiqaradi, sotadi, tarqatadi va sotadi. U onkologiya, gematologiya, immunologiya, kardiyologiya va nevrologiya uchun mahsulotlarni taklif etadi. Kompaniyaning mahsulotlari turli xil saraton kasalliklari uchun Opdivo; qattiq o'smalar uchun teri osti PD-1 inhibitori bo'lgan Opdivo Qvantig; faol revmatoid artrit va psoriatik artrit uchun Orencia; inoperable yoki metastatik melanomani davolash uchun Yervoy; anemiyani davolash uchun Reblozyl; takroriy yoki refrakter katta B-hujayrali limfomani davolash uchun Breyanzi; inoperable yoki metastatik melanomani davolash uchun Opdualag; va simptomatik obstruktsion HCMni davolash uchun Camzyosni o'z ichiga oladi. Shuningdek, u ko'p sklerozning takrorlanuvchi shakllarini davolash uchun Zeposia; takroriy yoki refrakter ko'p miyelomali bemorlarni davolash uchun Abecma; o'rta va og'ir blyashka psoriazini davolash uchun Sotyktu; KRASG12C mutatsiyasiga ega mahalliy rivojlangan yoki metastatik mayda hujayrali o'pka rakini (NSCLC) davolash uchun Krazati; va shizofreniyani davolash uchun Cobenfy taklif etadi. Bundan tashqari, u insult/tizimli emboliya xavfini kamaytirish va DVT/PEni davolash uchun Eliquis; ko'p miyelomani davolash uchun og'iz orqali yuboriladigan immunomodulyator dori Revlimid; ko'p miyeloma uchun Pomalyst/Imnovid; Filadelfiya xromosomasi-musbat surunkali miyeloid leykoz uchun Sprycel; va ko'krak bezi saratonini davolash uchun Abraxane taklif etadi. Bundan tashqari, u mahalliy rivojlangan yoki metastatik ROS1-musbat NSCLC; va NSCLC va oshqozon osti bezi saratonini davolash uchun Augtyro taqdim etadi. U mahsulotlarini ulgurji savdogarlar, distribyutorlar, maxsus dorixonalar, chakana savdogarlar, shifoxonalar, klinikalarga va hukumat idoralariga sotadi. Bristol-Myers Squibb kompaniyasi buyrak saratonida o'simta nazoratini ta'minlaydigan yangi davolash rejimini ishlab chiqish uchun Arcus Biosciences, Inc. bilan strategik hamkorlik qiladi. Kompaniya ilgari Bristol-Myers Company nomi bilan tanilgan. Kompaniya 1887 yilda tashkil etilgan va uning shtab-kvartirasi Nyu-Jersi shtatining Prinston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christopher S. Boerner Ph.D. | CEO & Chairman |
| Dr. Joseph J. Eiden Jr. | Head of Medical Affairs |
| Mr. Adam Lenkowsky | Executive VP & Chief Commercialization Officer |
| Mr. Charles E. Triano | SVP & Head of Investor Relations |
| Mr. Cristian Massacesi M.D. | Executive VP, Chief Medical Officer & Head of Development |
| Mr. David V. Elkins | Executive VP & CFO |
| Mr. Greg Meyers | Executive VP and Chief Digital & Technology Officer |
| Ms. Ahn Amanda Poole | Executive VP & Chief People Officer |
| Ms. Cari Gallman | Executive VP, General Counsel & Chief Policy Officer |
| Ms. Karin Shanahan | Executive VP, Chief Supply Chain & Operations Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-05 | 11-K | bmy-20260605.htm |
| 2026-05-08 | S-8 | ef20072737_s8.htm |
| 2026-05-08 | 8-K | ef20072750_8k.htm |
| 2026-04-30 | 8-K | bmy-20260430.htm |
| 2026-04-30 | 10-Q | bmy-20260331.htm |
| 2026-04-17 | DEFA14A | ef20070631_defa14a.htm |
| 2026-03-27 | 15-12G | ef20068734_1512g.htm |
| 2026-03-25 | DEFA14A | ef20067096_defa14a.htm |
| 2026-03-25 | DEF 14A | bmy-20260325.htm |
| 2026-03-25 | ARS | ef20068747_ars.pdf |